Key Takeaways
- A study involving more than 110,000 women found those taking GLP-1 medications were approximately 30% less likely to develop breast cancer than similar women not taking the medications.
- Researchers also observed lower rates of several obesity-related cancers, including colorectal, liver, pancreatic, and endometrial cancers.
- Scientists believe the benefits may extend beyond weight loss and could involve reduced inflammation, improved insulin sensitivity, and other metabolic effects.
- The findings highlight a growing shift in medicine from treating disease after it develops to identifying and reducing risk years earlier.
- At Lifespan Medical, we believe the best time to address disease is before it begins. If you’re interested in a proactive approach to your health, click here to learn more.
Learn more about Lifespan Medical’s preventative and on-going care services.
Most people know medications such as Ozempic, Wegovy, and Mounjaro as powerful tools for weight loss and diabetes management.
Now, researchers are exploring a surprising new possibility: could these medications also help reduce the risk of breast cancer?
At the 2026 American Society of Clinical Oncology (ASCO) meeting, researchers presented data suggesting women taking GLP-1 medications may have a substantially lower risk of developing breast cancer. One study involving more than 110,000 women found that those taking GLP-1 medications were approximately 30% less likely to develop breast cancer than comparable women not taking the medications.
Researchers also reported lower rates of several other obesity-related cancers, including colorectal, liver, pancreatic, and endometrial cancers.
Initially, scientists assumed any reduction in cancer risk would simply result from weight loss. Obesity is a well-established risk factor for many cancers. However, researchers are increasingly investigating whether GLP-1 medications may provide additional benefits by reducing inflammation, improving insulin regulation, and positively influencing other biological pathways linked to cancer development.
These findings are exciting, but it is important to keep them in perspective. The studies presented so far are observational, meaning they can identify important associations but cannot prove that the medications directly caused the reduction in cancer risk. Larger clinical trials will be needed before definitive conclusions can be drawn.
Perhaps the most exciting aspect of this research is what it represents. For decades, medicine has focused on diagnosing and treating disease after it develops. Increasingly, we are learning that many of the conditions people fear most—including heart disease, diabetes, dementia, and potentially some cancers—may be influenced years before symptoms appear. While more research is needed, GLP-1 medications are emerging as one of several tools that may help reduce long-term disease risk by improving metabolic health and addressing some of the underlying drivers of chronic illness.
At Lifespan Medical, we believe the best time to address disease is before it begins. If you’re interested in a proactive approach to your health, click here to learn more.